Pharmacological treatments in ARDS; a state-of-the-art update

  • Andrew James Boyle1, 2,

    Affiliated with

    • Rob Mac Sweeney2 and

      Affiliated with

      • Daniel Francis McAuley1, 2Email author

        Affiliated with

        BMC Medicine201311:166

        DOI: 10.1186/1741-7015-11-166

        Received: 12 March 2013

        Accepted: 11 June 2013

        Published: 20 August 2013

        Abstract

        Despite its high incidence and devastating outcomes, acute respiratory distress syndrome (ARDS) has no specific treatment, with effective therapy currently limited to minimizing potentially harmful ventilation and avoiding a positive fluid balance. Many pharmacological therapies have been investigated with limited success to date. In this review article we provide a state-of-the-art update on recent and ongoing trials, as well as reviewing promising future pharmacological therapies in ARDS.

        Keywords

        Acute lung injury Acute respiratory distress syndrome

        Introduction

        Despite its high incidence and devastating outcomes [1, 2], acute respiratory distress syndrome (ARDS) has no specific treatment, with effective therapy currently limited to minimizing potentially harmful ventilation and avoiding a positive fluid balance. ARDS is characterized by breakdown of the alveolar-capillary barrier, leading to flooding of the alveolar space producing the classical chest radiograph of bilateral pulmonary infiltrates. This non-cardiogenic pulmonary edema is associated with impaired oxygenation, as measured by the PaO2/FiO2 (P/F) ratio, with a lower P/F ratio indicating more severe hypoxia. Acute lung injury (ALI) is defined as a P/F ratio <300 mmHg (40kPa) and ARDS is a sub-group defined on the basis of more severely impaired oxygenation with a P/F ratio <200 mmHg (26.7 kPa).

        Since it was first described in 1967 [3], and despite over 40 years of research, few pharmacological therapies have emerged for ARDS. We limited the search strategy for this state-of-the-art update review to recent randomized controlled trials and meta-analyses, as well as a review of promising potential future pharmacological therapies in ARDS in an adult setting.

        Neuromuscular blockade

        Lung protective ventilation can be achieved in the majority of patients without using neuromuscular blockade (NMB) [4]; however, initial small studies eliminating patient effort via skeletal muscle inhibition with NMB improved patient-ventilator synchrony, as evidenced by reduced airway pressures and improved chest wall compliance. Therefore, in the severely hypoxemic ARDS patient, NMB may permit lower-pressure, lower-tidal volume ventilation with a consequent reduction in ventilator-induced lung injury. These beneficial effects led to a multi-center, randomized, placebo-controlled trial to assess the effect of NMB upon mortality [5] (Table 1). This showed that infusion with cisatracuriumbesylate within 48 hours of mechanical ventilation in patients with moderate ARDS improved 90-day survival. However, no difference was noted between the intervention and placebo groups until Day 20. The biological mechanism by which NMB improves late but not early outcome is unclear. While promising, the protective effect of neuromuscular blockade needs to be confirmed in a further phase 3 trial.
        Table 1

        Characteristics of trials to date

        Study title and abbreviation

        Design (all placebo-controlled)

        Population of ALI/ARDS A) Timing from ALI onset B) P/F ratio

        Number recruited

        Intervention

        Primary outcome

        Result (intervention vs control)

        Mortality (intervention vs control)

        Neuromuscular Blockade in Early ARDS [5]

        Phase 2 RCT

        A) 48 hours B) <150

        340

        Cisatracuriumbesylate: 15 mg initially, then 37.5 mg per hour for 48 hours

        90-day survival

        31.6% vs 40.7% (P= 0.08)

        28-day: 23.7% vs 33.3% (P= 0.05)

        The β-Agonist Lung Injury Trial (BALTI) [6]

        Phase 1 RCT

        A) 48 hours B) <300

        40

        Intravenous (IV) salbutamol for seven days (15 μg kg-1 h-1)

        Extravascular lung water (EVLW) at Day 7

        9.2 ± 6 vs 13.2 ±3 ml kg-1 (P= 0.04)

        28-day: 58% vs 66% (P= 0.4)

        Randomized, Placebo-Controlled Clinical Trial of an Aerosolized β2-Agonist for Treatment of Acute Lung Injury (ALTA) [7]

        Phase 2 RCT

        A) 48 hours B) < 300

        282

        Inhaled salbutamol (5 mg) every 4 hours for 10 days/24 hours after extubation

        Ventilator-free days (VFD)

        Stopped early 14.4 ± 0.9 vs 16.6 ± 0.9 (P= 0.087)

        Death before discharge: 24.3 ± 3.5 vs 18.5 ± 3.4 (P= 0.261)

        Effect of Intravenous β-2 Agonist Treatment on Clinical Outcomes in Acute Respiratory Distress Syndrome (BALTI-2) [8]

        Phase 2 RCT

        A) 72 hours B) <200

        326

        IV salbutamol for seven days (15 μg kg-1 (ideal body weight) h-1)

        28-day mortality

        Stopped early 34% vs 23% (P= 0.03)

         

        Neutrophil Elastase Inhibition in Acute Lung Injury (STRIVE) [9]

        Phase 3 RCT

        A) 48 hours B) <300

        492

        Sivelestat infusion

        1. 28-day mortality2. VFD

        Stopped early 1 26.6% vs 26% (P= 0.847)2. 11.4 ±10.27 vs 11.9 ± 10.1 (P= 0.536)

         

        Efficacy and Safety of Corticosteroids for Persistent ARDS (LaSRS) [14]

        Phase 2 RCT

        A) 7 to 28 days B) P/F <200

        180

        Moderate-dose IV methylprednisolone, for up to 25 days

        60-day mortality

        29.2% vs 28.6% (P= 1.0)

         

        Methylprednisolone Infusion in Early Severe ARDS [15]

        Phase 1 RCT

        A) 72 hours B) <300

        91

        Low-dose IV methylprednisolone, for up to 28 days

        Improvement in Lung Injury Score by Day 7

        69.8% vs 35.7% (P= 0.002)

        Hospital survival 76.2% vs 57.1% (P= 0.07)

        A Randomized Clinical Trial of Hydroxymethylglutaryl–Coenzyme A Reductase Inhibition for Acute Lung Injury (HARP) [19]

        Phase 2 RCT

        A) 48 hours B) <300

        60

        Simvastatin 80 mg daily, up to 14 days

        Reduction in EVLW indexed to actual body weight

        13.7 vs 13.4 (P= 0.90) Improvements in secondary outcomes

        Hospital survival: 19 vs 19 (P= 1.0)

        Nebulized Heparin is Associated with Fewer Days of Mechanical Ventilation in Critically Ill Patients: a Randomized Controlled Trial [21]

        Phase 2 RCT

        Patients expected to require ventilation for >48 hours, and within 24 hours of ventilation

        50

        Heparin 25,000 units every 4 to 6 hours, for up to 14 days

        Average daily P/F ratio

        194.2 ± 62.8 vs 187 ± 38.6 mmHg (P= 0.6) Improvements in secondary outcomes

        28-day: 20% vs 16% (P= 0.7)

        β-adrenergic agonists

        Alveolar edema is a central feature of ARDS, contributing to limitation of gaseous exchange and ventilatory failure. Experimental data suggest β-adrenergic agonists could accelerate alveolar fluid clearance, as well as provide cytoprotection, increased surfactant secretion and decreased endothelial permeability.

        Based on the proposed effect upon alveolar fluid clearance, the β-Agonist Lung Injury Trial (BALTI) randomized 60 patients to IV salbutamol or placebo for seven days [6]. In this small, single center study, salbutamol therapy significantly reduced extravascular lung water at Day 7 compared with placebo (Table 1).

        Subsequently, two large multi-center, randomized placebo-controlled trials were initiated. The first American study, ALTA (Albuterol Treatment for Acute Lung Injury) [7], enrolled 282 patients with ALI, but failed to demonstrate a difference in ventilator-free days between those receiving inhaled β-agonist therapy and those given placebo, and was stopped early as it breached the futility boundary (Table 1). In the most severely ill, as defined by the presence of shock at randomization, length of stay was significantly increased, suggesting worse outcome in this sub-group.

        BALTI-2 was a concurrent UK multi-center study investigating intravenous salbutamol in patients with ARDS, but was terminated early due to excess mortality in the group receiving IV salbutamol [8] (Table 1).

        On the basis of these larger trials, β-agonists should be avoided in patients with ALI. It is hypothesized that β-agonists may have a harmful cardiac effect, stimulating tachyarrhythmias and cardiac ischemia, resulting in a poorer outcome.

        Neutrophil elastase inhibitors

        Neutrophil elastase (NE) is a serine protease found in neutrophil granules and has a range of physiological effects, including anti-microbial actions and modification of tissue repair and inflammation. Excessive NE is capable of degrading endothelial basement membrane, and has been implicated in the pathogenesis of ARDS. Following a positive study in Japan, silvelestat, a neutrophil elastase inhibitor, was investigated in an international randomized, double-blind, placebo-controlled, multi-center phase III trial (STRIVE) [9] (Table 1). The study was stopped prematurely due to an increase in 180-day all-cause mortality.

        A more recent meta-analysis of eight clinical trials (including STRIVE) investigating silvelestat has shown it to have no effect on short-term mortality, and a worse outcome for 180-day mortality (Risk Ratio (RR) 1.27, CI 1.00 to 1.62) [10].

        Corticosteroids

        Given their effective anti-inflammatory properties, there has been extensive interest in the potential role of corticosteroids in both the prevention and treatment of ARDS. Different regimens have been investigated, varying from short courses of high-dose steroids to prolonged courses of lower doses.

        High dose corticosteroids do not prevent ARDS in at risk subjects [1113]. Therapeutically, both high-dose and moderate-dose steroids have so far failed to demonstrate efficacy in ARDS. An ARDSnet randomized, double-blind trial in 180 patients with ARDS for more than seven days, showed no effect of prolonged treatment with moderate-dose methylprednisolone compared to placebo [14] (Table 1). Although patients were liberated from mechanical ventilation earlier, patients receiving methylprednisolone were more likely to resume assisted ventilation, which was thought to be secondary to neuromuscular effects. In addition, initiation of treatment after 14 days of ARDS was associated with a harmful effect, with increased mortality at 60 and 180 days.

        However, the role of low-dose corticosteroids in established ARDS remains uncertain, with one study of 91 patients demonstrating prolonged low-dose methylprednisolone therapy reduces severity of lung injury by Day 7 of treatment [15] (Table 1).

        Despite a systematic review [16] and meta-analysis [17], the role of steroids in ARDS remains unclear, and in light of ongoing uncertainty, further trials are both planned (NCT01731795) and on-going (NCT01284452) (Table 2). It is also worth highlighting that the studies included used what are now considered injurious ventilation strategies. It remains uncertain if steroids provide benefit when combined with lung protective (and, therefore, less inflammatory) ventilator strategies.
        Table 2

        Ongoing/planned clinical trials in ARDS

        Study reference number

        Study title and abbreviation

        Design

        Population A) Timing B) P/F ratio

        Anticipated enrollment

        Intervention

        Primary outcome

        Status

        NCT01731795

        Efficacy Study of Dexamethasone to Treat the Acute Respiratory Distress Syndrome (DEXA-ARDS)

        Phase 2/3 RCT

        A) 24 hours from ARDS onset B) <200

        314

        Dexamethasone (20 mg/day for five days, then 10 mg/day for five days)

        Ventilator-free days

        Not yet recruiting

        NCT01284452

        Efficacy of hydrocortisone in treatment of severe sepsis/septic shock patients with ALI/ARDS

        Phase 2/3 RCT

        A) 12 hours from organ dysfunction B) <300

        194

        Hydrocortisone 50 mg every six hours for seven days

        28-day all-cause mortality

        Recruiting

        ISRCTN88244364

        Simvastatin in acute lung injury (HARP-2) [20]

        Phase 2/3 RCT

        A) 48 hours from ALI onset B) <300

        540

        Simvastatin 80 mg daily

        Ventilator-free days

        Recruiting

        NCT00979121

        Statins for Acutely Injured Lungs from Sepsis (SAILS)

        Phase 3 RCT

        A) 48 hours from ALI onset B) <300

        1000

        Rosuvastatin 20 mg daily

        Hospital mortality Day 60

        Recruiting

        ACTRN12612000418875

        Nebulized heparin for lung injury

        Phase 2 RCT

        A) Within 24 hours of mechanical ventilation in at-risk patients B) <300

        256

        Nebulised Heparin 25,000 international units, every six hours for up to 10 days

        Physical function assessed using physical function component of SF-36 health survey

        Not yet recruiting

        NCT01659307

        The effect of Aspirin on REducing iNflammation in human in vivo model of Acute lung injury (ARENA)

        Phase 2 RCT

        Healthy, non-smoking adults, using an LPS model of ALI

        33

        Aspirin 75 mg or Aspirin 1,200 mg

        Bronchalveolar lavage intraleukin-8 concentration

        Not yet recruiting

        NCT01504867

        LIPS-A: Lung Injury Prevention Study with Aspirin

        Phase 2 RCT

        Adults admitted to hospital via the emergency department at high-risk of developing ALI

        400

        Aspirin 325 mg Day 1, then 81 mg daily days 2 to 7

        Development of ARDS

        Recruiting

        ISRCTN95690673

        Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction (KARE) [28]

        Phase 2 RCT

        A) 48 hours from ALI onset B) <300

        60

        Palifermin 60 μg/kg IV daily for up to six days

        Oxygenation index at Day 7

        Recruiting

        ISRCTN27673620

        VItamiN D Replacement to Prevent Acute Lung Injury following OesophagectOmy (VINDALOO) [34]

        Phase 1/2 RCT

        Adults undergoing planned transthoracic esophagectomy

        80

        Oral Vitamin D (100,000 IU)

        EVLW at end of procedure

        Recruiting

        NCT00789685

        Safety, tolerability and preliminary efficacy of FP-1201 in ALI and ARDS

        Phase 1/2 Non-randomized

        A) 48 hours from ALI onset B) <300

        37

        Interferon-β, increasing dose over six days

        Clinically significant treatment emergent events, and all-cause mortality

        Completed

        Statins

        HMG CoA-reductase inhibitors (statins) have a range of physiological effects beyond their role in cholesterol reduction, including anti-inflammatory actions and endothelial function modulation. Their effect on pulmonary inflammation was confirmed during a randomized, double-blind, placebo-controlled pre-clinical study, where simvastatin demonstrated a variety of anti-inflammatory effects during an inhaled lipopolysaccharide (LPS) model of ARDS in healthy volunteers [18].

        A small phase II clinical trial in patients with ARDS (HARP) [19], suggested a potential role for simvastatin in the treatment of ARDS, with benefit in pulmonary and non-pulmonary organ dysfunction with no excess of adverse events in the intervention group (Table 1). Two larger trials are presently recruiting in the UK and Ireland (HARP-2 [20]) and in the USA (SAILS, NCT00979121), investigating simvastatin and rosuvastatin, respectively. A phase two trial in Oklahoma was recently terminated due to poor enrollment (NCT01195428).

        Heparin

        During the inflammatory process of ARDS fibrin is deposited throughout the alveolus, both intra- and extra-vascularly, impairing oxygenation. Experimental data show that, among other effects, heparin can reduce fibrin deposition. This led to a small study investigating the efficacy of nebulized heparin in patients at risk for ARDS [21]. Although there was no significant effect on the P/F ratio, this study suggested heparin may increase the number of ventilator-free days (VFD) (Table 1). The results of this trial have prompted further studies investigating the long-term impact of nebulized heparin in patients at risk of ARDS (ACTRN12612000418875) (Table 2).

        Aspirin

        During ARDS, platelets become activated and play an important role in disease progression by sequestering within the lung, forming micro-thrombi and attracting inflammatory cells to injured tissue. The potent anti-platelet effect of aspirin may offer a therapeutic approach to this pathological process. Observational data associated pre-hospital anti-platelet use with a reduction in subsequent ARDS incidence [22]. This finding was repeated in a separate study, although when propensity to receive aspirin was included in the analysis, the effect was lost [23].

        Clinical trials are planned to investigate the effect of aspirin on reducing inflammation in a human model of ARDS (ARENA, NCT01659307), while others are ongoing to assess the impact of aspirin in the prevention of ARDS (LIPS-A, NCT01504867) (Table 2).

        Angiotensin converting enzyme inhibitors/angiotensin receptor blockers

        The renin-angiotensin system (RAS) plays an important role in the pathogenesis of ARDS, with angiotensin converting enzyme 1 (ACE1) directing a RAS signal to the angiotensin 1 receptor (AT1R), mediating alveolar vasoconstriction, permeability and fibrosis. A variant of ACE1, ACE2, diverts a RAS signal to AT2R, which promotes alveolar vasodilation, decreased permeability and apoptosis, thus opposing the alternative potentially injurious signaling mechanism [24]. Angiotensin receptor blockers attenuate ventilator-induced lung injury in animal models [25], and ACE-inhibitor or angiotensin receptor blocker therapy on discharge were associated with reduced mortality in acute respiratory failure patients [26]. Collectively, these data provide encouragement for future clinical trials in this area.

        Stem cell therapy

        Regenerative medicine is an emerging field, using stem cells or growth factors to aid the repair of damaged tissue and organs. Stem cells exhibit anti-inflammatory, immunomodulatory and reparative effects, largely mediated through secreted growth factors, although cell to cell contact between stem cells and alveoli also mediates important effects [27].

        This prompts questions regarding the optimal delivery of stem cell therapy, as animal models of ARDS have shown survival to increase when treatment was delivered directly to the bronchial tree [28]. In addition, recent evidence in ex vivo human lung models of ALI support the investigation of delivering stem cells directly to the lung [29]. Clinical trials are awaited in this promising area.

        Growth factors

        Keratinocyte growth factor (KGF), an epithelial growth factor secreted by fibroblasts, has an important role in lung injury repair [30]. It increases alveolar cellular proliferation in ARDS, particularly of type II alveolar cells, enhancing repair. KGF may also have a role during the injurious process, reducing endothelial permeability and alveolar edema [30], and improving alveolar fluid clearance [31]. Following the completion of a small pre-clinical trial testing KGF in an LPS-model of ARDS (ISRCTN98813895), for which results are awaited, a phase II trial has commenced investigating the efficacy and safety of intravenous KGF (palifermin) in ARDS [32] (ISRCTN95690673) (Table 2).

        Other potential therapies

        Following data showing an immunomodulatory effect of vitamin D, animal models of ALI demonstrate that intra-tracheal administration of vitamin D can reduce neutrophil recruitment to the lung [33], which has obvious implications for future therapy in ALI. Vitamin D is currently being tested in patients at risk of developing ALI following esophagectomy [34] (Table 2).

        Used in the management of multiple sclerosis, interferon-β (IFN-β) has been shown in vitro and in animal models of ALI to reduce vascular leakage and improve capillary endothelial barrier function [35]. IFN-β therapy has been studied in a phase I/II study in the UK, for which results are awaited (NCT00789685) (Table 2).

        Finally, vascular endothelial growth factor (VEGF), an important molecule in the control of vascular permeability, has been found to be elevated in patients with ARDS [36]. The presence of VEGF inhibitors may prompt future randomized-controlled trials.

        Other therapies, including the use of nitric oxide [37], prostacyclin [38] and surfactant [39], have been investigated and found to be ineffective. These additional therapies, plus others, are beyond the scope of this review, but have been covered in recent review articles [40, 41]

        Conclusion

        Despite many interventions being studied, to date there has been little success in developing effective pharmacological therapies for the management of ARDS. However, given the high associated morbidity and mortality, pressure remains to continue efforts to improve outcomes. Increasing numbers of pharmacological therapies are being investigated, and with encouraging pre-clinical and early clinical results, it is expected that over the coming years some will develop into useful agents for the prevention and treatment of ARDS.

        Authors’ information

        AJB is an Academic Foundation Year Two trainee. RMS is a specialist registrar in anesthesia and intensive care medicine. DFM is a professor and consultant in intensive care medicine. DFM has received funding from the Northern Ireland Public Health Agency Research and Development Division Translational Research Group for Critical Care. AJB and RMS are employed by the Belfast Health and Social Care Trust, while DFM has a joint appointment between Belfast Health and Social Care Trust and Queen’s University Belfast.

        Abbreviations

        ACE: 

        Angiotensin converting enzyme

        ALI: 

        Acute lung injury

        ALTA: 

        Albuterol treatment for acute lung injury

        ARDS: 

        Acute respiratory distress syndrome

        ARENA: 

        The effect of Aspirin on REducing iNflammation in human in vivo model of Acute lung injury

        AT1R: 

        Angiotensin 1 receptor

        AT2R: 

        Angiotensin 2 receptor

        BALTI: 

        β-agonist Lung Injury Trial

        CI: 

        Confidence interval

        DEXA-ARDS: 

        Efficacy study of dexamethasone to treat the acute respiratory distress syndrome

        EVLW: 

        Extravascular lung water

        HARP: 

        A randomized clinical trial of hydroxymethylglutaryl–coenzyme a reductase inhibition for acute lung injury

        IFN-β: 

        Interferon-β

        IV: 

        Intravenous

        KGF: 

        Keratinocyte growth factor

        LIPS-A: 

        Lung injury prevention study with aspirin

        LPS: 

        Lipopolysaccharide

        NE: 

        Neutrophil elastase

        NMB: 

        Neuromuscular blockade

        P/F ratio: 

        PaO2/FiO2 ratio

        RAS: 

        Renin-angiotensin system

        RR: 

        Relative risk

        SAILS: 

        Statins for acutely injured lungs from sepsis

        STRIVE: 

        Neutrophil elastase inhibition in acute lung injury

        VEGF: 

        Vascular endothelial growth factor

        VFD: 

        Ventilator free days

        Declarations

        Acknowledgements

        AJB, RMS and DFM received no funding for writing this article.

        Authors’ Affiliations

        (1)
        Centre for Infection and Immunity, Health Sciences Building, Queen’s University Belfast
        (2)
        Regional Intensive Care Unit, Royal Victoria Hospital

        References

        1. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD: Incidence and outcomes of acute lung injury. N Engl J Med 2005, 353:1685–1693.PubMedView Article
        2. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, Cooper AB, Guest CB, Mazer CD, Mehta S, Stewart TE, Barr A, Cook D, Slutsky AS: One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003, 348:683–693.PubMedView Article
        3. Ashbaugh D, Boyd Bigelow D, Petty T, Levine B: Acute respiratory distress in adults. Lancet 1967, 290:319–323.View Article
        4. The Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000, 342:1301–1308.View Article
        5. Papazian L, Forel J-M, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Arnal J-M, Perez D, Seghboyan J-M, Constantin J-M, Courant P, Lefrant J-Y, Guérin C, Prat G, Morange S, Roch A: Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010, 363:1107–1116.PubMedView Article
        6. Perkins GD, McAuley DF, Thickett DR, Gao F: The β-Agonist Lung Injury Trial (BALTI) a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006, 173:281–287.PubMedView Article
        7. The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network: Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011, 184:561–568.View Article
        8. Smith FG, Perkins GD, Gates S, Young D, McAuley DF, Tunnicliffe W, Khan Z, Lamb SE: Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet 2012, 379:229–235.View Article
        9. Zeiher BG, Artigas A, Vincent J-L, Dmitrienko A, Jackson K, Thompson BT, Bernard G: Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med 2004, 32:1695–1702.PubMedView Article
        10. Iwata K, Doi A, Ohji G, Oka H, Oba Y, Takimoto K, Igarashi W, Gremillion DH, Shimada T: Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. Intern Med 2010, 49:2423–2432.PubMedView Article
        11. Weigelt JA, Norcross JF, Borman KR, Snyder WH 3rd: Early steroid therapy for respiratory failure. Arch Surg 1985, 120:536–540.PubMedView Article
        12. Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, Duncan RC, Tendler MD, Karpf M: The effects of high-dose corticosteroids in patients with septic shock. N Engl J Med 1984, 311:1137–1143.PubMedView Article
        13. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF: Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988, 138:62–68.PubMedView Article
        14. The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network: Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006, 354:1671–1684.View Article
        15. Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, Gibson M, Umberger R: Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007, 131:954–963.PubMedView Article
        16. Deal EN, Hollands JM, Schramm GE, Micek ST: Role of corticosteroids in the management of acute respiratory distress syndrome. Clin Ther 2008, 30:787–799.PubMedView Article
        17. Peter JV, John P, Graham PL, Moran JL, George IA, Bersten A: Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ 2008, 336:1006–1009.PubMedView Article
        18. Shyamsundar M, McKeown STW, O’Kane CM, Craig TR, Brown V, Thickett DR, Matthay MA, Taggart CC, Backman JT, Elborn JS, McAuley DF: Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 2009, 179:1107–1114.PubMedView Article
        19. Craig TR, Duffy MJ, Shyamsundar M, McDowell C, O’Kane CM, Elborn JS, McAuley DF: A randomized clinical trial of hydroxymethylglutaryl– coenzyme a reductase inhibition for acute lung injury (the HARP study). Am J Respir Crit Care Med 2011, 183:620–626.PubMedView Article
        20. McAuley DF, Laffey JG, O’Kane CM, Cross M, Perkins GD, Murphy L, McNally C, Crealey G, Stevenson M, the HARP-2 investigators on behalf of the Irish Critical Care Trials Group: Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trial. Trials 2012, 13:170.PubMedView Article
        21. Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ: Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 2010, 14:R180.PubMedView Article
        22. Erlich JM, Talmor DS, Cartin-Ceba R, Gajic O, Kor DJ: Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. Chest 2011, 139:289–295.PubMedView Article
        23. Kor DJ, Erlich J, Gong MN, Malinchoc M, Carter RE, Gajic O, Talmor DS: Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit Care Med 2011, 39:2393–2400.PubMedView Article
        24. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui C-C, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM: Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005, 436:112–116.PubMedView Article
        25. Yao S, Feng D, Wu Q, Li K, Wang L: Losartan attenuates ventilator-induced lung injury. J Surg Res 2008, 145:25–32.PubMedView Article
        26. Noveanu M, Breidthardt T, Reichlin T, Gayat E, Potocki M, Pargger H, Heise A, Meissner J, Twerenbold R, Muravitskaya N, Mebazaa A, Mueller C: Effect of oral β-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study. Crit Care 2010, 14:R198.PubMedView Article
        27. Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K, Rowlands DJ, Quadri SK, Bhattacharya S, Bhattacharya J: Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 2012, 18:759–765.PubMedView Article
        28. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA: Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007, 179:1855–1863.PubMed
        29. Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA: Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 2013, 187:751–760.PubMedView Article
        30. Ware LB, Matthay MA: Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am J Physiol Lung Cell Mol Physiol 2002, 282:L924-L940.PubMed
        31. Matthay MA, Goolaerts A, Howard JP, Lee JW: Mesenchymal stem cells for acute lung injury: preclinical evidence. Crit Care Med 2010, 38:S569-S573.PubMedView Article
        32. Cross LJ, O’Kane CM, McDowell C, Elborn JJ, Matthay MA, McAuley DF: Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction – a randomised placebo-controlled trial (KARE): study protocol. Trials 2013, 14:51.PubMedView Article
        33. Takano Y, Mitsuhashi H, Ueno K: 1α,25-dihydroxyvitamin D3 inhibits neutrophil recruitment in hamster model of acute lung injury. Steroids 2011, 76:1305–1309.PubMedView Article
        34. Parekh D, Dancer RC, Lax S, Cooper MS, Martineau AR, Fraser WD, Tucker O, Alderson D, Perkins GD, Gao-Smith F, Thickett DR: Vitamin D to prevent acute lung injury following oesophagectomy (VINDALOO): study protocol for a randomised placebo controlled trial. Trials 2013, 14:100.PubMedView Article
        35. Kiss J, Yegutkin GG, Koskinen K, Savunen T, Jalkanen S, Salmi M: IFN-β protects from vascular leakage via up-regulation of CD73. Eur J Immunol 2007, 37:3334–3338.PubMedView Article
        36. Ware LB, Kaner RJ, Crystal RG, Schane R, Trivedi NN, McAuley D, Matthay MA: VEGF levels in the alveolar compartment do not distinguish between ARDS and hydrostatic pulmonary oedema. Eur Respir J 2005, 26:101–105.PubMedView Article
        37. Adhikari NKJ, Burns KEA, Friedrich JO, Granton JT, Cook DJ, Meade MO: Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ 2007, 334:779–779.PubMedView Article
        38. Afshari A, Brok J, Møller AM, Wetterslev J: Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Cochrane Database Syst Rev 2010., CD007733:
        39. Spragg RG, Taut FJH, Lewis JF, Schenk P, Ruppert C, Dean N, Krell K, Karabinis A, Günther A: Recombinant Surfactant Protein C–based Surfactant for Patients with Severe Direct Lung Injury. Am J Respir Crit Care Med 2011, 183:1055–1061.PubMedView Article
        40. Mac Sweeney R, McAuley DF: Pharmacological therapy for acute lung injury. Open Crit Care Med J 2010, 3:7–19.
        41. Raghavendran K, Pryhuber GS, Chess PR, Davidson BA, Knight PR, Notter RH: Pharmacotherapy of acute lung injury and acute respiratory distress syndrome. Curr Med Chem 2008, 15:1911–1924.PubMedView Article
        42. Pre-publication history

          1. The pre-publication history for this paper can be accessed here: http://​www.​biomedcentral.​com/​1741-7015/​11/​166/​prepub

        Copyright

        © Boyle et al.; licensee BioMed Central Ltd. 2013

        This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.